ĐÁNH GIÁ BƯỚC ĐẦU HIỆU QUẢ CỦA MOLNUPIRAVIR TRONG ĐIỀU TRỊ BỆNH NHÂN COVID-19 TẠI BỆNH VIỆN QUÂN DÂN Y MIỀN ĐÔNG

Thị Tuyết Lang Phạm; Thị Huyền Nguyễn; Thị Thúy Loan Lê; Thị Ân Nguyễn; Hoàng Việt Trương; Phạm Trọng Khang Hà; Đức Công Nguyễn

doi:10.59354/ydth175.2022.54

Keywords:

COVID-19 patient, molnupiravir, PCR

Abstract

Background: The coronavirus (COVID-19) pandemic remains a global burden. Manifestations of the disease range from asymptomatic to respiratory failure, multi-organ failure, and sepsis. Evaluating the effectiveness of antiviral drugs can help to apply in treatment to prevent these dangerous complications.

Objective: To determine the effectiveness of molnupiravir in the treatment of patients with mild-moderate COVID-19 at Eastern Military Hospital from October 2021 to December 2021.

Methods: Descriptive study, performed on 225 hospitalized patients with mild-moderate COVID-19 whose history, clinical symptoms and COVID-19 virus were investigated. Patients were treated with standard regimen, or standard regimen plus molnupiravir, and viral load was assessed on day 1 and 10.

Results: In the 225 study patients, the negative rate for COVID-19 in the standard treatment group was 25%, in the molnupiravir group it was 30.4%. The research showed that molnupiravir reduced the time of viral clearance with p<0,001. In patients who remained positive for COVID-19 on day 10, patients treated with molnupiravir had a lower viral load on day 10 than the standard treatment group (p=0,049).

Conclusion: Preliminary assessment of molnupiravir resulted in a significant reduction in viral load in patients with mild-moderate COVID-19.

References

Azer, S A (2020). “COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics.” New microbes and new infections vol. 37.

Abdelnabi R, Foo CS, De Jonghe S, Maes P, Weynand B, Neyts J (2021). “Molnupiravir inhibits the replication of the emerging SARS-CoV-2 variants of concern (VoCs) in a hamster infection model”. J Infect Dis, 224:749-53.

Sheahan TP, Sims AC, Zhou S, et al (2020). “An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice”. Sci Transl Med,12(541):eabb5883.

Fischer W, Eron JJ, Holman W, et al (2021). “Molnupiravir, an Oral Antiviral Treatment for COVID-19”. Preprint. medRxiv.

Jayk Bernal, Angélica et al. (2022). “Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.” The New England journal of medicin, 386,6: 509-520.

Bộ Y tế (2021), “Quyết định số 4689/QĐ-BYT về việc ban hành Hướng dẫn chẩn đoán và điều trị COVID-19”.

Kamal, Lina & Ramadan, Ahmed & Farraj, Suha & Bahig, Lydia & Ezzat, Sameera (2022). “The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review”. Saudi Pharmaceutical Journal.

“Efficacy and safety of molnupiravir (MK-4482) in hospitalized adult participants with COVID-19 (MK- 4482-001)” – ClinicalTrials.gov (Ngày truy cập 23/04/2022).

Fact sheet for healthcare providers: Emergency use authorization for healthcare providers. https://www.fda. gov/media/155054/download (Truy cập ngày 03/08/2022)